<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106231</url>
  </required_header>
  <id_info>
    <org_study_id>NMRR-21-767-59240</org_study_id>
    <nct_id>NCT05106231</nct_id>
  </id_info>
  <brief_title>Effectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus Education</brief_title>
  <acronym>EPICCIHKDMEP</acronym>
  <official_title>Effectiveness of Pharmacy Integrated Community Care (PICC) Improving Hemoglobin A1c (HBA1C) and Knowledge in Diabetes Mellitus (DM) Education Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Centre, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Centre, Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ministry of Health Malaysia designs an education program for diabetes mellitus under the&#xD;
      &quot;Know Your Medicine&quot; campaign. The program called Pharmacy Integrated Community Care (PICC)&#xD;
      hopes to improve knowledge and self-care for diabetes mellitus patients. PICC contains four&#xD;
      modules that will provide knowledge on diabetes mellitus in an interactive, easy understand&#xD;
      and fun program. The investigators are interested in evaluating the effectiveness of the&#xD;
      program in order to see its relevance to Malaysian.&#xD;
&#xD;
      PICC is an education program to give knowledge on diabetes mellitus to the patients. It&#xD;
      intended to improve self-care knowledge to patients with underlying Type 2 Diabetes Mellitus&#xD;
      conducted to whole Malaysia. However, in Sarawak, the investigators interested in conducting&#xD;
      it together with this is an experimental study, which aims to examine the effectiveness of&#xD;
      PICC. The study is being conducted in the nine Sarawak Division. A minimum of 94 respondents&#xD;
      will be participating in this study. Your profile details will be taken with strict&#xD;
      confidentiality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study title: Effectiveness of Pharmacy Integrated Community Care (PICC) improving Hemoglobin&#xD;
      A1c (HBA1C) and Knowledge in diabetes mellitus (DM) education program&#xD;
&#xD;
      Study Population: The study population will be local people living in Sarawak from multiple&#xD;
      racial backgrounds with underlying type 2 diabetes mellitus (T2DM). The investigators recruit&#xD;
      patients with underlying T2DM mellitus who obtain medication at the primary Government Health&#xD;
      Clinic in each district.&#xD;
&#xD;
      Study Design: The study's design will be a prospective, multicenter and parallel-design&#xD;
      single-blind randomised controlled with two treatment groups. The trial evaluates a PICC's&#xD;
      effectiveness in improving HBA1C involving four-session structured group-based intervention&#xD;
      (SGBI) of a two to three-hour pharmacist-led program with follow up evaluations. The control&#xD;
      arm will have the same syllabus without SGBI.&#xD;
&#xD;
      General Objective:&#xD;
&#xD;
        1. To describe and critically appraised DM education studies.&#xD;
&#xD;
        2. To examine the program's effectiveness versus control in improving medication adherence&#xD;
           with underlying T2DM in the Sarawak State of Malaysia.&#xD;
&#xD;
      Specific Objectives:&#xD;
&#xD;
        1. To measure the effectiveness of PICC in improving HbA1C, fasting blood glucose and&#xD;
           understanding&#xD;
&#xD;
        2. To investigate the sustainability of the program.&#xD;
&#xD;
      Study endpoints/outcomes:&#xD;
&#xD;
      Primary outcome: HbA1C will be the primary outcome. The investigators will collect this by&#xD;
      using a point of care test.&#xD;
&#xD;
      Secondary outcome: Investigating knowledge and understanding of DM medication management will&#xD;
      be evaluated using the quizzes in the PICC program.&#xD;
&#xD;
      Sample Size: A previous study has shown a standard deviation of 1.5. Suppose the true&#xD;
      difference between the experimental and control means is 1, 36 experimental subjects and 36&#xD;
      control subjects with a probability (power) of 0.8. By estimating 30% dropout or incomplete&#xD;
      data, a minimum sample size of 94 (47 for each group).&#xD;
&#xD;
      Study Duration: 1 October to 31 January 2022.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The study's design will be a prospective, multicenter and parallel-design single-blind randomised controlled with two treatment groups. The trial evaluates a PICC's effectiveness in improving HBA1C involving four-session structured group-based intervention (SGBI) of a two to three-hour pharmacist-led program with follow up evaluations. The control arm will have the same syllabus without SGBI.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>For the blinding of researchers, they remain blinded towards the stage of publication. During the post-intervention follow up, the researchers still are blinded by the participants' allocation, as the Sarawak Pharmacy Service Division keeps the participant list with group allocation. None of the instruments distributed to the participants will disclose their name and group assignment to assure the blinding among researchers who do the data analyses. Only after this study's results are published, the blinding or the codes will be broken through the return of the participants' list to the principal investigator. The Sarawak Pharmacy Service Division will maintain the randomisation codes throughout the study without disclosing them to the researchers or the participants. No breaking code procedure is necessary for this study as the intervention of this study is educational and does not involve the investigation of medicinal products (IMP).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C improvement (HbA1c level below 42mmol/mol or 6.5%) using finger prick test</measure>
    <time_frame>4 months</time_frame>
    <description>PICC education influencing change in HBA1C (HbA1c level below 42mmol/mol or 6.5% -CDC guideline on diabetes) using finger prick test within 4 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes knowledge improvement (scores in percentage)</measure>
    <time_frame>4 months</time_frame>
    <description>PICC improved diabetic knowledge scores (score above or equal to 80% up to 100% showing good knowledge)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>PICC arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the intervention group will attend the PICC program, which will take four-month and each session 2.5 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to the control group will receive a normal lecturer with the same syllabus with PICC and end up with quizzes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PICC Program</intervention_name>
    <description>Participants will attend the PICC program which consists of 4 sessions that involved Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.</description>
    <arm_group_label>PICC arm</arm_group_label>
    <other_name>Pharmacy Integrated Community Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>The control arm received one lecture session with the same PICC syllabus; however, the delivery is only slide shows and a lecture. At the end of the session, we will conduct a quiz.</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Diabetic Lecture</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. were non-pregnant adults &gt;18 years of age regardless of gender or ethnicity;&#xD;
&#xD;
          2. spoke and understood Bahasa Malaysia&#xD;
&#xD;
          3. had a medical record showing haemoglobin A1c test (HbA1c) level of ≥6.3% (45 mmol/mol)&#xD;
             and fasting plasma glucose test (FPG) ≥7.0 mmol/L&#xD;
&#xD;
          4. Patients also need to be able to provide informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants were excluded if they could not answer the quizzes independently or had a&#xD;
             hearing or vision impairment.&#xD;
&#xD;
          2. Patients unable to read, write and speak Malay, medically unstable or unable to&#xD;
             provide informed consent will be excluded.&#xD;
&#xD;
          3. Patients who are currently attending intensive psychological treatment, hospitalised&#xD;
             and participating in other studies will also be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamarudin Ahmad, B.Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jabatan Farmasi, Hospital Miri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamarudin Ahmad, B.Pharm</last_name>
    <phone>+60128789869</phone>
    <email>kamarudin8888@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lim Su Eee, B.Pharm</last_name>
    <phone>+60128975022</phone>
    <email>limsuee@moh.gov.my</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik Kesihatan Daro</name>
      <address>
        <city>Daro</city>
        <state>Sarawak</state>
        <zip>96200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kho Boon Yan, B.Pharm</last_name>
      <phone>+60168535210</phone>
      <email>khoboonyan@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Kapit</name>
      <address>
        <city>Kapit</city>
        <state>Sarawak</state>
        <zip>96800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngu Chiew Pin, B.Pharm</last_name>
      <phone>+60149052065</phone>
      <email>ngu.chiew.pin@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Jalan Masjid Kuching</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93050</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lim Su Ee, B.Pharm</last_name>
      <phone>+60128975022</phone>
      <email>limsuee@moh.gov.my</email>
    </contact>
    <contact_backup>
      <last_name>Izzul Syazwan Syuib, B.Pharm</last_name>
      <phone>+60196134326</phone>
      <email>izzulsyazwan@moh.gov.my</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Anchah, B.Pharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliet Lau Lu Lin, B.Pharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Bandar Miri</name>
      <address>
        <city>Miri</city>
        <state>Sarawak</state>
        <zip>98000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamarudin Ahmad, B.Pharm</last_name>
      <phone>+60128789869</phone>
    </contact>
    <contact_backup>
      <last_name>Chai Min Choo, B.Pharm</last_name>
      <phone>+60138942182</phone>
      <email>chaimc@moh.gov.my</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Pusa</name>
      <address>
        <city>Pusa</city>
        <state>Sarawak</state>
        <zip>94950</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiu Kuan Chia, B.Pharm</last_name>
      <phone>+60198175536</phone>
      <email>kiukc@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Sarikei</name>
      <address>
        <city>Sarikei</city>
        <state>Sarawak</state>
        <zip>96100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Ting Siew Shin, B.Pharm</last_name>
      <phone>+60168553766</phone>
      <email>amytss@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Siburan</name>
      <address>
        <city>Serian</city>
        <state>Sarawak</state>
        <zip>94200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KENNY GOH WEI CHUAN, B.Pharm</last_name>
      <phone>+60128904729</phone>
      <email>kenny_gwc@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Jalan Oya</name>
      <address>
        <city>Sibu</city>
        <state>Sarawak</state>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Poh Yin, B.Pharm</last_name>
      <phone>+60123688188</phone>
      <email>changpy@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Kesihatan Sri Aman</name>
      <address>
        <city>Simanggang</city>
        <state>Sarawak</state>
        <zip>95000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Wong Siew King, B.Pharm</last_name>
      <phone>+60128583961</phone>
      <email>farmasi.kksriaman@moh.gov.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>https://www.spirit-statement.org/</url>
    <description>The protocol is written following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist.</description>
  </link>
  <reference>
    <citation>Ting CY, Adruce SAZ, Hassali MA, Ting H, Lim CJ, Ting RS, Jabar AHAA, Osman NA, Shuib IS, Loo SC, Sim ST, Lim SE. Correction to: Effectiveness and sustainability of a structured group-based educational program (MEDIHEALTH) in improving medication adherence among Malay patients with underlying type 2 diabetes mellitus in Sarawak State of Malaysia: study protocol of a randomized controlled trial. Trials. 2019 May 10;20(1):267. doi: 10.1186/s13063-019-3348-x.</citation>
    <PMID>31077233</PMID>
  </reference>
  <reference>
    <citation>Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011 Jan;4(1):8-11. doi: 10.4103/0974-1208.82352.</citation>
    <PMID>21772732</PMID>
  </reference>
  <reference>
    <citation>Soto-Greene ML, Salas-Lopez D, Sanchez J, Like RC. Antecedents to effective treatment of hypertension in Hispanic populations. Clin Cornerstone. 2004;6(3):30-6; discussion 37-8. Review.</citation>
    <PMID>15707260</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Research Centre, Malaysia</investigator_affiliation>
    <investigator_full_name>Kamarudin Bin Ahmad</investigator_full_name>
    <investigator_title>Chief Pharmacist, Miri Hospital Sarawak</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>Type2 diabetes</keyword>
  <keyword>group based intervention</keyword>
  <keyword>patient integrated community care (PICC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data collection forms are not in codes. Site investigators and participants have access to individual case report forms because the information is transparent to those involved.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT05106231/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

